

DOCKET NO.: DAVI-0005/2393063/PP5895
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

David James Craik

Confirmation No.: 1485

Application No.: 09/787,082

Group Art Unit: 1653

Filing Date: June 14, 2001

Examiner: Chih Min Kam

For: CYCLISED CONOTOXIN PEPTIDES

DATE OF DEPOSIT: *Sept 8, 2003*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

PATENT

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;
or

☒ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith

EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:

- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. _____, filed _____.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

DOCKET NO.: DAVI-0005/2393063/PP5895
PATENT

- 4 -

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date: September 8, 2003



Leslie E. Aberman
Registration No. P54,836

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2003 WW



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. DAVI-0005/ 2393063/MJC/RR	Application No. 09/787,082
	Applicant David James Craik, et al.	
	Filing Date June 14, 2001	Group 1653
	Confirmation No. 1485	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

5	Al-Obeidi, F., et al., "Potent and prolonged acting cyclic lactam analogues of α -melanotropin: design based on molecular dynamics," <i>J. Med. Chem.</i> , 1989 , 32, 2555-2561
6	Armishaw, C.J., et al., "Synthesis of backbone cyclic analogues of α -conotoxin IMI by chemoselective ligation of unprotected linear precursors," Benedetti, E., et al. (Eds.), <i>Peptides</i> , 2002 , 1 page (Abstract)
7	Armishaw C.J., et al., "Synthesis of N to C terminal cyclic analogues of α -conotoxin ImI by chemoselective ligation of unprotected linear precursors," <i>Peptides: The Wave of the Future</i> , Lebl, M., et al. (Eds.), <i>American Peptide Society</i> , 2001 , 113-114
8	Botti, P., et al., "Cyclic peptides from linear unprotected peptide precursors through thiazolidine formation," <i>J. Am. Chem. Soc.</i> , 1996 , 118, 10018-10024
9	Byk, G., et al., "Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P," <i>J. Med. Chem.</i> , 1996 , 39, 3174-3178
10	Charpentier, B., et al., "Synthesis and binding affinities of cyclic and related linear analogues of CCK ₈ selective for central receptors," <i>J. Med. Chem.</i> , 1989 , 32, 1184-1190
11	Chazin, W.J., et al., "Comparative studies of conformation and internal mobility in native and circular basic pancreatic trypsin inhibitor by ¹ H nuclear magnetic resonance in solution," <i>Eur. J. Biochem.</i> , 1985 , 152, 429-437
12	Chu, V., et al., "Thermodynamic and structural consequences of flexible loop deletion by circular permutation in the streptavidin-biotin system," <i>Protein Science</i> , 1998 , 7, 848-859
13	Claeson, P., et al., "Fractionation protocol for the isolation of polypeptides from plant biomass," <i>J. Nat. Prod.</i> , 1998 , 61, 77-81
14	Feng, Y., et al., "Circular permutation of granulocyte colony-stimulating factor," <i>Biochemistry</i> , 1999 , 38, 4553-4563

EXAMINER


DATE CONSIDERED



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. DAVI-0005/ 2393063/MJC/RR	Application No. 09/787,082
	Applicant David James Craik, et al.	
	Filing Date June 14, 2001	Group 1653
	Confirmation No. 1485	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	15	Garrett, J.B., et al., "Are turns required for the folding of ribonuclease T1?," <i>Protein Science</i> , 1996 , 5, 204-211
	16	Gilon, C., et al., "Backbone cyclization: a new method for conferring conformational constraint on peptides," <i>Biopolymers</i> , 1991 , 31, 745-750
	17	Goldenberg, D.P., et al., "Circular and circularly permuted forms of bovine pancreatic trypsin inhibitor," <i>J. Mol. Biol.</i> , 1983 , 165, 407-413
	18	Goldenberg, D.P., et al., "Folding pathway of a circular form of bovine pancreatic trypsin inhibitor," <i>J. Mol. Biol.</i> , 1984 , 179, 527-545
	19	Goldenberg, D.P., "Dissecting the roles of individual interactions in protein stability: lessons from a circularized protein," <i>J. Cellular Biochemistry</i> , 1985 , 29, 321-335
	20	Gray, W.R., et al., "Conotoxin MI – Disulfide bonding and conformational states," <i>J. Biological Chemistry</i> , October 25, 1983 , 258(20), 12247-12251
	21	Gutknecht, R., et al., "The glucose transporter of <i>Escherichia coli</i> with circularly permuted domains is active <i>in vivo</i> and <i>in vitro</i> ," <i>J. Biological Chemistry</i> , October 2, 1998 , 273(40), 25745-25750
	22	Hennecke, J., et al., "Conversion of a catalytic into a structural disulfide bond by circular permutation," <i>Biochemistry</i> , 1998 , 37, 17590-17597
	23	Hruby, V.J., "Design of peptide hormone and neurotransmitter analogues," <i>TIPS</i> , June 1985 , 259-262
	24	Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups," <i>Life Sciences</i> , 1982 , 31(3), 189-199
EXAMINER		DATE CONSIDERED




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. DAVI-0005/ 2393063/MJC/RR	Application No. 09/787,082
	Applicant David James Craik, et al.	
	Filing Date June 14, 2001	Group 1653
	Confirmation No. 1485	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

25	Jackson, D.Y., et al., "Enzymatic cyclization of linear peptide esters using subtiligase," <i>J. Am. Chem. Soc.</i> , 1995 , <i>117</i> , 819-820
26	Jacobsen, R.B., et al., "A novel D-leucine-containing conus peptide: diverse conformational dynamics in the contryphan family," <i>J. Peptide Res.</i> , 1999 , <i>54</i> , 93-99
27	Kreitman, R.J., "A circularly permuted recombinant interleukin 4 toxin with increased activity," <i>Proc. Natl. Acad. Sci. USA</i> , July 1994 , <i>91</i> , 6889-6893
28	Kreitman, R.J., et al., "Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma," <i>Cancer Research</i> , August 1, 1995 , 3357-3363
29	Lender, A., et al., "Design and synthesis of sulfur-free cyclic hexapeptides which contain the RGD sequence and bind to the fibrinogen GP IIb/IIIa," <i>Int. J. Peptide Protein Res.</i> , 1993 , <i>42</i> , 509-517
30	Muir, T.W., et al., "Expressed protein ligation: a general method for protein engineering," <i>Proc. Natl. Acad. Sci. USA</i> , June 1998 , <i>95</i> , 6705-6710
31	Myers, R.A., et al., "Conus peptides as chemical probes for receptors and ion channels," <i>Chem. Rev.</i> , 1993 , <i>93</i> , 1923-1936
32	Okumu, F.W., et al., "Effect of restricted conformational flexibility on the permeation of model hexapeptides across caco-2 cell monolayers," <i>Pharmaceutical Res.</i> , 1997 , <i>14</i> (2), 169-175
33	Olivera, B.M., et al., "Minireview: Conotoxins," <i>J. Biological Chemistry</i> , November 25, 1991 , <i>266</i> (33), 22067-22070
34	Olivera, B.M., "Diversity of <i>Conus</i> neuropeptides," <i>Science</i> , July 20, 1990 , <i>249</i> , 257-250

EXAMINER	DATE CONSIDERED
-----------------	------------------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. DAVI-0005/ 2393063/MJC/RR	Application No. 09/787,082
	Applicant David James Craik, et al. Filing Date June 14, 2001 Group 1653 Confirmation No. 1485	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

35	Pallaghy, P.K., et al., "A common structural motif incorporating a cystine knot and a triple-stranded β -sheet in toxic and inhibitory polypeptides," <i>Protein Science</i> , 1994 , 3, 1833-1839
36	Rivier, J.E., et al., "Bicyclic gonadotropin releasing hormone (GnRH) antagonists," <i>Peptides Chemistry, Structure and Biology</i> , 1990 , 33-37
37	Rote, K.V., et al., "Circular pancreatic trypsin inhibitor: A novel substrate for studies on intracellular proteolysis," <i>J. Biological Chemistry</i> , January 15, 1989 , 264(2), 1156-1162
38	Saether, O., et al., "Elucidation of the primary and three-dimensional structure of the uterotonic polypeptide kalata B1," <i>Biochemistry</i> , 1995 , 34, 4147-4158
39	Tam, J.P., et al., "Thia zip reaction for synthesis of large cyclic peptides: mechanisms and applications," <i>J. Am. Chem. Soc.</i> , 1999 , 121, 4316-4324
40	Tam, J.P., et al., "Synthesis of large cyclic cystine-knot peptide by orthogonal coupling strategy using unprotected peptide precursor," <i>Tetrahedron Letters</i> , 1997 , 38(32), 5599-5602
41	Tam, J.P., "A biomimetic strategy in the synthesis and fragmentation of cyclic protein," <i>Protein Science</i> , 1998 , 7, 1583-1592
42	Terada, S., et al., "Synthesis and hydrolysis by pepsin and trypsin of a cyclic hexapeptide containing lysine and phenylalanine," <i>Eur. J. Biochem.</i> , 1975 , 52, 273-282
43	Wieligmann, K., et al., "Eye lens β B2-crystallin: circular permutation does not influence the oligomerization state but enhances the conformational stability," <i>J. Mol. Biol.</i> , 1998 , 280, 721-729
44	Zhang, L., et al., "Synthesis and application of unprotected cyclic peptides as building blocks for peptide dendrimers," <i>J. Am. Chem. Soc.</i> , 1997 , 119, 2363-2370

EXAMINER

DATE CONSIDERED



Sheet 5 of 5

Form PTO-1449 ModifiedList of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)U.S. Department of Commerce
Patent and Trademark OfficeDocket No.
DAVI-0005/
2393063/MJC/RRApplication No.
09/787,082Applicant
David James Craik, et al.Filing Date
June 14, 2001Group
1653Confirmation No.
1485**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	45	5,589,356	12/31/96	Tam	435	68.1

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	46	WO 96/34878	11/07/96	PCT		
	47	WO 98/28434	07/02/98	PCT		
	48	WO 98/56807	12/17/98	PCT		

EXAMINER	DATE CONSIDERED
----------	-----------------